Oncternal Therapeutics, Inc. (ONCT), a clinical-stage biopharmaceutical company, is specializing in developing oncology therapies for cancers that have critical unmet medical needs. Amongst its clinical pipeline is the humanized monoclonal antibody, Zilovertamab, which binds to Receptor-Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-216, a small molecule designed to inhibit the biological activity of ETS-family transcription factor oncoproteins, that is presently in a Phase 1/2 clinical trial. Further to this, the company is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) therapy to treat hematologic malignancies and solid tumors, targeting ROR1. This CAR-T therapy is currently undergoing a Phase 1/2 clinical trial. In addition, Oncternal Therapeutics, Inc. is also developing ONCT-534, a dual-action androgen receptor inhibitor product candidate that is still in preclinical development, designed to help treat castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has entered into licensing agreements with several organizations, including the Regents of the University of California, Georgetown University, and The University of Texas M.D. Anderson Cancer Center, and Shanghai Pharmaceutical (USA) Inc. among others. The company also has a research collaboration with Celularity Inc. aimed at investigating placental derived-cellular therapies targeting ROR1. Overall, Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Oncternal Therapeutics, Inc.'s ticker is ONCT
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 11-50 employees working at Oncternal Therapeutics, Inc.
It is https://www.oncternal.com/
Oncternal Therapeutics, Inc. is in the Healthcare sector
Oncternal Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Oncternal Therapeutics, Inc.'s industry peers: